European Notebook: EC Pharma Policy Reorganized; Early Access To Medicines Scheme Starts; U.K. Changing Merger Regs
Executive Summary
Changes in responsibilities in new European Commission were welcomed by industry but not by health activists; and a brain cancer vaccine being developed by American biotech is selected to pioneer new early access scheme for innovative drugs being set up in the U.K.
You may also be interested in...
EFPIA Trumpets EU-Wide Solution To Drug Theft After Italian Report
Europe is largely ignoring drugs theft while focusing on medicines counterfeiting, but a new Italian report could spur stakeholders to unify behind EFPIA's supply chain tracking system.
Amgen Amps Up T-VEC Story At ASCO With Filing Plans And Combos
Amgen will file the cancer immunotherapy talimogene laherparepvec for the treatment of metastatic melanoma later this year, although the product’s larger commercial potential likely lies om combination with other immunotherapies.
Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.